- Home
- IVVD vs ANGO Comparison
IVVD vs ANGO Comparison
Compare IVVD & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVVD | ANGO |
|---|---|---|
| Founded | 2020 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 659.8M | 530.2M |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | IVVD | ANGO |
|---|---|---|
| Price | $2.11 | $10.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $8.75 | ★ $19.33 |
| AVG Volume (30 Days) | ★ 3.2M | 838.9K |
| Earning Date | 11-06-2025 | 01-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $50,039,000.00 | ★ $307,306,000.00 |
| Revenue This Year | $107.86 | $9.11 |
| Revenue Next Year | $146.53 | $4.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 332.71 | 7.26 |
| 52 Week Low | $0.35 | $8.27 |
| 52 Week High | $3.07 | $13.99 |
Technical Indicators
Market Signals| Indicator | IVVD | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.99 | 37.48 |
| Support Level | $2.15 | $10.16 |
| Resistance Level | $2.31 | $10.90 |
| Average True Range (ATR) | 0.19 | 0.66 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 2.90 | 17.53 |
Price Performance
Historical ComparisonAbout IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.